Below are the most recent publications written about "Germ-Line Mutation" by people in Profiles.
-
van Bergen T, Bosch DA, Bellann?-Chantelot C, Mulet-Lazaro R, Bledsoe JR, Chen L, de Looper HWJ, van Dijk C, Ter Borg MND, Bindels EMJ, Hoogenboezem RM, Roovers O, Olofsen PA, Bartels M, van Montfrans J, Breed P, Salzer E, Holierhoek MG, Nelken B, Beaupain B, Fleming MD, Shimamura A, Raaijmakers MHGP, Donadieu J, Newburger PE, Touw IP, Aalbers AM. Germ line LCP1 mutations cause immunodeficiency with neutropenia, monocytopenia, lymphopenia, and defective cytokinesis. Blood Adv. 2026 Feb 10; 10(3):627-641.
-
Comiskey DF, Liyanarachchi S, Wu J, Sheikh MS, Hendrickson IV, Brock PL, Ringel MD, Nieminen TT. Identification of Rare Noncoding Variants in Familial Nonmedullary Thyroid Carcinoma. Thyroid. 2026 Feb; 36(2):169-176.
-
Conry M, Ostrovnaya I, Kemel Y, Sinha S, Baughn LB, Avery B, Maclachlan K, Groner V, Banaszak L, Norman A, Boddicker NJ, Clay-Gilmour A, Kumar S, Kim E, Dandiker S, Waghmare M, Slager S, Sborov DW, Garber J, Brown EE, Hildebrandt M, Hari P, Camp N, Vachon C, Usmani S, Offit K, Joseph V. Multiple myeloma risk linked to DNA damage response genes. J Hematol Oncol. 2026 Jan 06; 19(1):10.
-
Mateos MK, Ajuyah P, Fuentes-Bolanos N, El-Kamand S, Barahona P, Altekoester AK, Mayoh C, Holliday H, Liu J, Cui L, Pfaff E, Mackay A, Resnick AC, Pinese M, Lau LMS, Khuong-Quang DA, Dias K, Goudie C, Salkeld A, Rokita JL, Jones DTW, Juretic N, Hayden E, Pfister SM, Kramm CM, Blattner-Johnson M, Jabado N, Tsoli M, Vittorio O, Mueller S, Guo Y, Tucker K, Waszak SM, Perreault S, Jones C, Wong-Erasmus M, Cowley MJ, Ziegler DS. Germline analysis of an international cohort of pediatric diffuse midline glioma patients. Neuro Oncol. 2025 Sep 08; 27(7):1849-1863.
-
Li CM, Cordes A, Oliphant MUJ, Quinn SA, Thomas M, Selfors LM, Silvestri F, Girnius N, Rinaldi G, Zoeller JJ, Shapiro H, Tsiobikas C, Gupta KP, Pathania S, Regev A, Kadoch C, Muthuswamy SK, Brugge JS. Brca1 haploinsufficiency promotes early tumor onset and epigenetic alterations in a mouse model of hereditary breast cancer. Nat Genet. 2024 Dec; 56(12):2763-2775.
-
Ahmad MH, Hegde M, Wong WJ, Mohammadhosseini M, Garrett L, Carrascoso A, Issac N, Ebert B, Silva JC, Pihan G, Zhu LJ, Wolfe SA, Agarwal A, Liu PP, Castilla LH. Runx1-R188Q germ line mutation induces inflammation and predisposition to hematologic malignancies in mice. Blood Adv. 2023 12 12; 7(23):7304-7318.
-
Roch AM, Kim RC, Nguyen TK, House MG, Zyromski NJ, Nakeeb A, Schmidt CM, Ceppa EP. Patients with deleterious germline mutations: A heterogeneous population for pancreatic cancer screening? J Surg Oncol. 2023 Aug; 128(2):289-294.
-
Majhi PD, Sharma A, Jerry DJ. Genetic modifiers of p53: opportunities for breast cancer therapies. Oncotarget. 2023 03 24; 14:236-241.
-
Seabrook A, Wijewardene A, De Sousa S, Wong T, Sheriff N, Gill AJ, Iyer R, Field M, Luxford C, Clifton-Bligh R, McCormack A, Tucker K. MEN4, the MEN1 Mimicker: A Case Series of three Phenotypically Heterogenous Patients With Unique CDKN1B Mutations. J Clin Endocrinol Metab. 2022 07 14; 107(8):2339-2349.
-
Davidoff DF, Benn DE, Field M, Crook A, Robinson BG, Tucker K, De Abreu Lourenco R, Burgess JR, Clifton-Bligh RJ. Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study. J Clin Endocrinol Metab. 2022 04 19; 107(5):e1907-e1916.